Company Quick10K Filing
Arcturus Therapeutics
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 11 $54
10-Q 2019-05-13 Quarter: 2019-03-31
10-K 2019-03-18 Annual: 2018-12-31
20-F 2018-05-14 Annual: 2017-12-31
20-F 2017-04-28 Annual: 2016-12-31
20-F 2016-03-04 Annual: 2015-12-31
20-F 2015-02-27 Annual: 2014-12-31
20-F 2014-03-28 Annual: 2013-12-31
8-K 2019-08-01 Enter Agreement, Other Events, Exhibits
8-K 2019-06-18 Enter Agreement, Sale of Shares, Officers, Regulation FD, Exhibits
8-K 2019-05-20 Shareholder Vote
8-K 2019-05-13 Earnings, Exhibits
8-K 2019-03-18 Earnings, Exhibits
8-K 2019-02-27 Regulation FD, Exhibits
8-K 2019-02-08 Regulation FD, Other Events, Exhibits

Arcturus Therapeutics Financials

ARCT Metrics, Comps, Filings

Annual | Quarterly

Business

Arcturus Therapeutics Ltd. ("we," "us," "Arcturus," or the "Company") is an RNA medicines company focused on significant opportunities in rare diseases with a current focus on liver and respiratory diseases. In addition to our internal mRNA platform, our proprietary lipid nanopartical deliver system, LUNAR®, enables multiple nucleic acid medicines. The Company's internet address is https://arcturusrx.com/. The Company was founded in 2013. On November 15, 2017, Alcobra Ltd. acquired Arcturus Therapeutics, Inc. ("Arcturus Inc.") pursuant to a merger between the companies. Immediately after giving effect to the merger, on November 15, 2017, Alcobra Ltd. changed its name to Arcturus Therapeutics Ltd. On November 16, 2017, the Company commenced trading on the Nasdaq Global Market under the symbol "ARCT." On February 11, 2019, we disclosed our intention to initiate a process to redomicile from an Israeli limited company to a U.S. corporation, as described more fully under "Redomiciliation," below.

The Company's principal executive offices are located in San Diego, California. Our key proprietary technology has the potential to address the major hurdles in RNA development, namely the effective and safe delivery of RNA therapeutics to disease-relevant target tissues. We believe the versatility of our platform to target multiple tissues, its compatibility with various nucleic acid therapeutics, and our expertise in developing scalable manufacturing processes puts us in a good position to deliver on the next generation of nucleic medicines.

• We have deep expertise in the discovery and development of RNA medicines, including key experience in the production of RNA drug substance and nanoparticle-formulated drug product.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Newtek Business Services (NEWT) 102,397 50% 14.4 1% 203,186 119,953 38,166 19,019 2,644 6,825 97,995
AquaBounty Technologies (AQB) 61,340 14% -5.2 -32% 36,775 7,056 158 23 -11,942 -10,756 55,565
Arcturus Therapeutics (ARCT) 53,595 0% -4.8 -15% 44,419 38,065 4,350 0 -6,884 -6,712 32,213
Chart Acquisition (CACG) 37,032 -96.2 -1% 29,842 8,652 0 0 -414 -384 36,965
US Gold (USAU) 21,724 -2.5 -86% 8,772 384 0 0 -7,583 -7,147 18,185
1st Franklin Financial (FFC) 3,210 -0.2 7% 833,128 581,983 0 0 58,119 81,934 -17,598
Source Capital (SOR)
BlackRock TCP Capital (TCPC)
Accelerated Pharma (ACCP)
Financial Federal (FIF)
Pelican Financial (PFI)
MainStay MacKay DefinedTerm Municipal Opportunitie (MMD)
Sutter Rock Capital (SSSS)
General American Investors (GAM)
CM Finance (CMFN)
Pioneer (PIO)
Safeco (SAF)
Firsthand Technology Value Fund (SVVC)
OHA Investment (OHAI)
Flag Financial (FLAG)

Balance Sheet ($'000)2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash22,0952,17616,6582,30425,23836,816
Accounts Receivable4804,481
Inventory
PP&E79972272401,0491,975
Assets50,32422,31871,68351,56852,02444,198
Accounts Payable47305575281,7902,398
Long-Term Debt10,300
Liabilities1,6362,3752,3524,34018,23030,556
Stockholders' Equity48,68819,94369,33147,22833,79413,642
Income Statement ($'000)2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue12,99815,753
Cost of Revenue
Gross Profit
R&D7,06625,10513,46118,39115,91816,982
SG&A3,2245,8394,9925,3577,57220,582
Tax-1751731
Net Income-10,548-32,834-19,449-24,603-10,902-21,785
Cash Flow ($'000)2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating-7,353-28,326-18,148-19,241-460-20,760
Cash Investing-28,0478,407-33,8424,88110,35522,134
Cash Financing57,398066,47266,99810,204